[0006a]

In one aspect, the present disclosure refers to a use of agent comprising 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient in the manufacture of a medicament for treating Down syndrome in a patient in need thereof, wherein the patient is a patient with mild to moderate Alzheimer's disease and Down syndrome.

Problem to be Solved by the Invention

[0007]

Drugs which suppress progress of AD by inhibiting neurodegeneration need to be developed early. An object of the present invention is to provide a drug and a method which suppress progress of disease in which the amount of Aβ in the brain is increased, such as AD.

Means for Solving Problem

CLAIMS

[Claim 1] Use of agent comprising 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient in the manufacture of a medicament for treating Down syndrome in a patient in need thereof, wherein the patient is a patient with mild to moderate Alzheimer's disease and Down syndrome.

[Claim 2] The use according to claim 1, wherein an amount of amyloid β protein in the brain of the patient is reduced by increasing an amount of amyloid β protein in cerebrospinal fluid.

[Claim 3] The use according to claim 1 or 2, wherein the medicament is to be orally administered once a day in a dose of 100 mg to 400 mg in terms of 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

[Claim 4] The use according to claim 1 or 2, wherein the medicament is to be orally administered once a day in a dose of 160 mg or 320 mg in terms of 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

[Claim 5] The use according to any one of claims 1 to 4, wherein the medicament is to be administered to the patient with a disease in which the amount of amyloid β protein in the brain is increased.

[Claim 6] The use according to any one of claims 1 to 4, wherein the medicament is to be administered to the patient with Alzheimer's disease, Probable Alzheimer's disease, Possible Alzheimer's disease, Preclinical Alzheimer's disease, Prodromal Alzheimer's disease, or mild cognitive impairment.

[Claim 7] The use according to any one of claims 1 to 4, wherein the medicament is to be administered to the patient with Alzheimer's disease, or mild cognitive impairment.

[Claim 8] The use according to any one of claims 6-7, wherein the mild cognitive impairment is mild cognitive impairment due to Alzheimer’s disease (MCI due to AD).